Burgdorf – Ypsomed (SIX: YPSN) completed the sale of its subsidiary Ypsotec on 31 October 2025. The sale is part of the strategic orientation of the Ypsomed Group with the aim of focusing on its core competencies in the field of medical technology …
Burgdorf – Ypsomed launches YpsoLoop, the first autoinjector platform designed for circularity. The two new 1 ml and 2 ml platform versions enable material recovery through a design enabling automated disassembly and efficient recycling, while …
Burgdorf – Ypsomed will establish its first manufacturing facility in the United States. The company has selected Holly Springs in Wake County, North Carolina, as the location and will invest around CHF 200 million in a first phase. This is another …
Burgdorf – Ypsomed celebrated the topping-out ceremony for its second plant in Schwerin with over 200 guests from politics, business, and the construction trade. With “Schwerin 2,” the company is investing more than half a billion Swiss francs over …
Burgdorf – Ypsomed (SIX: YPSN) is set to capture significant growth in multiple existing and emerging drug delivery markets and announces a mid-term ambition to reach total sales between CHF 0.9 and 1.1 billion and an EBIT between CHF 280 and 340 …
Burgdorf – The U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for SmartPilot, a digital connectivity add-on developed by Ypsomed. The device transforms the YpsoMate autoinjector into a connected system that automatically …
Burgdorf – Ypsomed Holding AG (SIX: YPSN) announced today that it has successfully completed the sale of its Ypsomed Diabetes Care business to TecMed AG.
Burgdorf – At the Annual General Meeting of Ypsomed Holding AG (SIX: YPSN) held on 2 July 2025, the shareholders approved all proposals put forward by the Board of Directors. Marie-Pierre Zerr was newly elected to the Board of Directors. Gilbert …
Burgdorf – A new chapter in the treatment of obesity begins with the approval of the world's first dual GCG/GLP-1 receptor agonist drug delivered using an Ypsomed autoinjector in China. Innovent Biologics, Inc. (XHKG: 1801), a leading Chinese …
Burgdorf – On 26 June 2025, Ypsomed opened its first dedicated production site in China with a festive ceremony. The new facility, located in Changzhou’s high-tech industrial park near Shanghai, was completed in just 14 months and marks a further …
Burgdorf – Ypsomed (SIX: YPSN) and CamDiab announce their agreement to integrate mylife Loop automated insulin delivery (AID) system with Abbott’s next-generation dual glucose-ketone sensor, which is currently under development.
Burgdorf – Ypsomed (SIX: YPSN), in partnership with CamDiab, is continuing the successful rollout of the iOS version of the mylife CamAPS FX app, the controller component of the automated insulin delivery (AID) system, mylife Loop. In combination …
Burgdorf, 21.05.2025, 07:00 a.m. – Ypsomed (SIX: YPSN) continues its growth trajectory and achieved consolidated sales of CHF 748.9 million in the financial year 2024/25 (prior year: CHF 548.5 million). Adjusted for the divested pen needle and blood …
Burgdorf – Ypsomed (SIX:YPSN) and TecMed AG (TecMed) have entered into an agreement for the sale of Ypsomed diabetes care business for up to CHF 420 million, including earn-out. TecMed is a company based in Burgdorf, controlled by Willy Michel. …
Burgdorf – Ypsomed (SIX: YPSN) and Sidekick Health are launching an integrated digital health solution to better support people with obesity. Ypsomed's autoinjectors seamlessly integrate into Sidekick’s digital health and chronic condition …
Burgdorf – With a formal groundbreaking ceremony yesterday, Ypsomed officially launched the construction of its second production facility in Schwerin. As part of the “Schwerin 2” project, the site will be expanded over the coming years in two …
Burgdorf –The winners of the Ypsomed Innovation Award 2025 were honoured yesterday evening at the EVENTfabrik in Bern. First place went to Yuon Control AG. Xemperia and Santella also made it onto the winners' podium. The Innovation Award, which …
Burgdorf – Ypsomed (SIX: YPSN) continues its growth trend and achieved consolidated sales of CHF 255.4 million in the first six months of the 2023/24 financial year (previous year: CHF 244.2 million).
Burgdorf – Ypsomed (SIX: YPSN) announced a strategic collaboration with BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, to advance self-injection solutions for …
Burgdorf – Today Ypsomed celebrates the opening of a new production hall at its German site in Schwerin. The expansion will enable the company to increase its production capacity to meet the growing global demand for high-quality medical technology …
Burgdorf – Ypsomed and Medical Technology and Devices S.p.A. (MTD) have completed the sale of the pen needle and blood glucose monitoring (BGM) systems business. This transaction marks a pivotal moment for Ypsomed, as it allows the company to focus …
Burgdorf – The Annual General Meeting of Ypsomed Holding AG (SIX: YPSN) approved all proposals of the Board of Directors on 26 June 2024. Around 500 shareholders attended the event in Burgdorf. They confirmed all members of the Board of …
Burgdorf – medac GmbH has selected an autoinjector from Ypsomed for the relaunch of its methotrexate pen. The YpsoMate 1.0 will gradually replace the current metoject/metex PEN, introducing a model that offers patients enhanced ease of use. The …
Burgdorf – Ypsomed (SIX: YPSN) continues its growth trend and achieved consolidated sales of CHF 548.5 million in the financial year 2023/24 (previous year: CHF 497.5 million). Adjusted for the sale of the diabetes specialist DiaExpert, this …
Burgdorf – Ypsomed enters a partnership with ten23 health, a global Swiss contract development and manufacturing organization. The aim of this collaboration is to advance the commercialization of the YpsoDose wearable injector for the subcutaneous …
Burgdorf - Ypsomed (SIX: YPSN) and Medical Technology and Devices S.p.A. (MTD) have signed an agreement on the transfer of the pen needle and blood glucose monitoring systems (BGMs) businesses. The transfer to MTD will ensure the long-term supply of …
Burgdorf, 15.11.2023, 07:00 a.m. – Ypsomed (SIX: YPSN) continues its growth trend and achieved consolidated sales of CHF 255.4 million in the first six months of the 2023/24 financial year (previous year: CHF 244.2 million).
Burgdorf – Ypsomed announces new Human Factors (HF) services for its pharmaceutical partners to reinforce its position as a leading developer and manufacturer of self-injection solutions. By enhancing its device platform offering with integrated …
Burgdorf, 29.09.2023, 7:00 a.m. – Ypsomed (SIX: YPSN) announces a change in its Executive Board. After more than twenty years, Niklaus Ramseier will hand over his functions as Chief Financial Officer (CFO) on 31 March 2024 and will continue to be …
Burgdorf – Ypsomed will build a conference and cultural centre in Solothurn and make it available for public events. This was announced yesterday by Simon Michel, CEO of Ypsomed, at a celebratory event attended by numerous guests, including the Mayor …
Burgdorf – Ypsomed (SIX: YPSN) has concluded a long-term supply agreement with Novo Nordisk for large quantities of autoinjectors. The autoinjectors will be used to administer drugs for the self-treatment in various metabolic indications. Ypsomed is …
Burgdorf – The Annual General Meeting of Ypsomed Holding AG (SIX: YPSN) approved all proposals of the Board of Directors on 28 June 2023. More than 360 shareholders attended the event in Burgdorf. They confirmed all members of the Board of Directors …
Burgdorf – Ypsomed (SIX: YPSN) will expand its offering of digital health solutions together with S3 Connected Health in the future. S3 Connected Health, headquartered in Dublin, Ireland is a specialist digital health partner for life science …
Burgdorf – Ypsomed (SIX: YPSN) continues its growth trend and achieved consolidated sales of CHF 497.5 million in the 2022/23 financial year (previous year: CHF 464.8 million). Adjusted for the effect of the divestment of DiaExpert, continuing …
Burgdorf – Ypsomed (SIX: YPSN) is building a new production hall in Schwerin and creating 60 new jobs in the process. The company held the groundbreaking ceremony last Friday thus signaling the start of the construction for the 3300 square meters of …
Burgdorf – On 25 April 2023, the groundbreaking ceremony for Ypsomed's (SIX: YPSN) new production facility took place in the Changzhou National Hi-tech District. In order to be able to efficiently serve the rapidly growing Chinese market for …
Burgdorf – Ypsomed announces a change in its Executive Board. After more than thirty years with Ypsomed and formerly Disetronic, Dr Beat Maurer will retire as Chief Legal Officer (CLO) on 31 March 2023. He will be succeeded by Dr Nicolas Meyer, who …
Burgdorf - The winners of the Ypsomed Innovation Award 2022 were honoured yesterday evening at the PwC Switzerland New Year's Apéro in Bern. The winners are machineMD (1st place), Pace Locator (2nd place) and Compact Motion (3rd place). The …
Burgdorf – Ypsomed (SIX: YPSN) and Mediq are completing the sale of DiaExpert. The transaction strengthens Ypsomed's focus on the development, manufacture and distribution of its own high-quality medical technology products for people with chronic …
Burgdorf – Eli Lilly and Company (NYSE: LLY) has decided to fully focus on its successful drug portfolio. Therefore, Lilly decided to stop the joint project with Ypsomed (SIX: YPSN) to enter the US insulin pump market in 2026. Ypsomed plans to submit …
Burgdorf – Ypsomed (SIX: YPSN) is on track and achieved consolidated sales of CHF 244.2 million in the first half of the 2022/23 financial year (previous year: CHF 222.6 million). This corresponds to a growth of 9.7% compared with the previous year. …
Burgdorf – Ypsomed (SIX: YPSN) and Mediq have signed an agreement on the sale of DiaExpert. DiaExpert is an established specialist and mail-order retailer for the care of people with diabetes in Germany, specialised in insulin pump therapy. With the …
Burgdorf – Ypsomed (SIX: YPSN) has developed a new autoinjector platform for liquid medications with volumes ranging from 1.5 to 5.5 ml. The YpsoMate 5.5 is the latest addition to the growing YpsoMate family of devices and is based on the established …
Burgdorf – Ypsomed (SIX: YPSN) and Sidekick Health today announced a collaboration to extend Ypsomed’s device and SmartServices offering by implementing a self-injection module in Sidekick’s proven digital therapeutics solution. The combination of …
Burgdorf – Ypsomed's Annual General Meeting on 29 June 2022 approved all the proposals of the Board of Directors. It elected Gilbert Achermann as the new Chairman of the Board of Directors and Simon Michel as a new member of the Board of Directors. …
Burgdorf – Ypsomed (SIX: YPSN) has completed the capital increase in the full amount of one million new shares very successfully. The subscription and placement price was set at CHF 122.50 after the expiry of the subscription and placement period, …
Burgdorf – The Board of Directors of Ypsomed (SIX: YPSN) decided in its meeting on Monday, 13 June 2022, to carry out a capital increase from authorised capital created by the resolution of the Annual General Meeting on Wednesday, 30 June 2021, in …
Burgdorf – Ypsomed (SIX: YPSN) generated a growth in sales of 15.2% in the financial year 2021/22 compared to the previous year and achieved a consolidated turnover of CHF 464.8 million (previous year: CHF 403.7 million). On its continued growth …
Burgdorf – Ypsomed (SIX: YPSN) announces changes to the Board of Directors. The founder and Chairman of the Board of Directors of the Ypsomed Group Dr. h.c. Willy Michel will not stand for re-election as Chairman and member of the Board of Directors …
Burgdorf – With the aim of focusing on changing customer needs, Ypsomed is stepwise optimizing the organisation of the business units and the Management Board.
Burgdorf – Ypsomed (SWX: YPSN) generated a growth in turnover of 11.6% in the first half of 2021/22 compared to the previous year and achieved a consolidated total turnover of CHF 222.6 million. On its continued growth trend, the company achieved an …
Burgdorf – Ypsomed has introduced the world’s first autoinjector for prefilled syringes with integrated connectivity. The YpsoMate On combines the advantages of the proven YpsoMate autoinjector with the options of digital therapy support. The …
Burgdorf – The Annual General Meeting of the Ypsomed Group on 30 June 2021 approved all proposals of the Board of Directors. The AGM elected Ms Betül Susamis Unaran as a new member of the Board of Directors and authorised the Board to increase the …
Burgdorf – Today, eight companies representing the pharmaceutical supply chain for pharma products announced the founding of the Alliance to Zero, a non-profit membership association for pharma and biotech supply chain companies that aims to …
Burgdorf – Ypsomed (SWX: YPSN) increased its consolidated sales by CHF 9.4 million to CHF 403.7 million in the financial year 2020/21 (prior year: CHF 394.3 million). The two business segments developed differently during the Corona pandemic: while …
Burgdorf – Ypsomed (SWX: YPSN) has reached an agreement in its legal dispute with Insulet Corp. (NASDAQ: PODD). Insulet acknowledges the contractually agreed fee and compensates Ypsomed for the termination of the cooperation with an additional USD …
Burgdorf / Mainz / Basel – Ypsomed advances its patch injector into a comprehensive solution by entering into a collaboration with SCHOTT, one of the leading suppliers of pharmaceutical primary packaging, and Lonza, a leading global partner of the …
Burgdorf – Ypsomed (SWX: YPSN) increased sales by 4.6% or CHF 8.7 million in the first six months of 2020/21 compared to the previous year, and generated an operating profit (EBIT) of CHF 8.3 million. The company continued on its growth course in a …
Burgdorf – Ypsomed has developed the world’s first zero carbon emission prefilled autoinjector. The YpsoMate Zero is based on the proven YpsoMate autoinjector platform that offers convenient handling and patient safety. The new YpsoMate Zero uses …
Burgdorf – Yesterday, the Annual General Meeting of the Ypsomed Group has approved all proposals and has elected Gilbert Achermann as a new member of the Board of Directors and of the Compensation Committee to succeed Anton Kräuliger. Gilbert …
Burgdorf – In the financial year 2019/20, Ypsomed achieved consolidated sales of CHF 393.9 million (previous year: CHF 453.8 million). In the previous year, Ypsomed generated a turnover of 352.8 million in continuing operations. On this comparative …
Burgdorf – Teva Pharmaceutical Industries Ltd. (Teva), a global leader in generic medicines with innovative treatments in select areas, including central nervous system, pain and respiratory, launches its drug product AJOVY® in the pre-filled …
We are monitoring the global development after the outbreak of the Coronavirus very closely. Our highest priority is our business continuity and the reliable supply of our products as well as the safety of our employees. We can confirm that to date …
Burgdorf – Ypsomed is recording weaker growth in the insulin pump business and is adjusting its approval strategy with the American FDA. In addition, Ypsomed is reducing its EBIT outlook for the current financial year 2019/20 to CHF 9 million due to …
Burgdorf – Terumo Corporation (Terumo), a leading global manufacturer and distributor of medical devices, will fill its PLAJEX™ syringe with the drug Teribone™ and assemble it with the YpsoMate prefilled autoinjector from Ypsomed. Teribone™ is a …
Burgdorf – Ypsomed achieved a consolidated total turnover of CHF 190.6 million during the first half-year of the business year 2019/20. EBIT from continuing operations increased by 71 %, the Ypsomed Delivery Systems segment grew by 33.8 %. The …
Burgdorf – Ypsomed opens its new and renovated buildings at the headquarters in Burgdorf. With this expansion, Ypsomed secures the additional capacities and workplaces it needs to continue growing in the future.
Burgdorf – Ypsomed opens its new production plant in Schwerin, in north-eastern Germany. Ypsomed is thus ensuring the necessary production capacities for growth in the coming years. Around 200 jobs will be created at the new production site over the …
Burgdorf – In the financial year 2018/19, Ypsomed achieved consolidated sales of CHF 453.8 million (previous year: CHF 466.1 million). In continuing operations, Ypsomed achieved a sales growth of CHF 68.4 million, which represents an increase of 24%. …
Burgdorf – Teva Pharmaceutical Industries Ltd. (Teva), a global leader in generic medicines with innovative treatments in select areas, including CNS, pain and respiratory, has launched its drug product Copaxone® in the pre-filled autoinjector …
Burgdorf – No agreement has been reached between Ypsomed and Insulet Corp., its former supplier of Omnipod® devices on the amount of the expiration fee payable to Ypsomed under the terms of the distribution agreement that expired in June 2018. After …
Burgdorf – Terumo Corporation (Terumo), a leading global manufacturer and distributor of medical devices, will fill its PLAJEX™ syringe with the drug Hulio® and assemble it with the YpsoMate prefilled autoinjector from Ypsomed. Hulio® is a biosimilar …
Burgdorf – Ypsomed increased sales by CHF 45.3 million in the first half year of 2018/19. The operating result (EBIT) amounts to CHF 68.4 million. The result includes a CHF 49.8 million compensation from Insulet Corp. in terms of revenue and profit. …
Burgdorf and Eindhoven (NL) – Ypsomed, a leading developer and manufacturer of injection and infusion systems for self-medication, and Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced a collaboration to …
Burgdorf/Schwerin - The topping-out ceremony for Ypsomed's new production plant took place on 28 June 2018. The Swiss medical technology company is building a new production plant in Schwerin's industrial park, creating around 150 new jobs in the …
Burgdorf - On 27 June 2018, the Annual General Meeting of the Ypsomed Group elected Paul Fonteyne as a new member of the Board of Directors and the Compensation Committee of the Ypsomed Group. He is Chairman of Boerhinger Ingelheim USA, and until …
Burgdorf – In the business year 2017/18, Ypsomed generated consolidated sales of CHF 466.1 million (prior year: CHF 389.6 million). Compared with the previous year, this represents an increase in sales of 19.7%. The operating results (EBIT) increased …
Burgdorf – Ypsomed establishes its first subsidiary in North America, Canada. The foundation in Canada is another important milestone in the consistently pursued growth strategy. At the same time, the mylife™ YpsoPump® insulin pump is launched in …
Burgdorf - The guidance of CHF 60 million EBIT for the 2017/18 financial year announced in November 2017 remains unchanged. Ypsomed is investing in its global expansion and the establishment of new subsidiaries for the insulin pump business. Ypsomed …
Burgdorf - Swisscom and Ypsomed have been cooperating since the spring of 2017 to develop application options for the latest generation of mobile communications. Ypsomed has digitised selected production processes with 5G. This simplifies …
Burgdorf – Ypsomed continues to expand its offers for digital diabetes therapy with the launch of the mylife™ App. The mylife™ App is connected to the mylife™ YpsoPump® insulin pump via Bluetooth® and continuously records current therapy data. …
.jpg)
